{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:49:26Z","timestamp":1791139766660,"version":"4.1.0"},"reference-count":162,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disorder due to damage of the nigrostriatal pathway and consequent dopamine (DA) deficiency. The main classic symptoms are those related to motor disturbances, such as postural instability, resting tremor, bradykinesia, and muscle rigidity. Other symptoms, such as non-motor symptoms, do not attract the attention of clinicians and are often overlooked, remaining undiagnosed and untreated, even though they can significantly impair quality of life of PD patients. Dopaminergic therapy is primarily aimed at treating motor symptoms, although it can bring measurable benefits for various non-motor problems. This narrative review analyzes the scientific literature and describes the most recent information on the impact of dopaminergic therapy on non-motor symptoms in PD; both its beneficial and undesirable effects. We discuss evidence that non-motor symptoms such as cardiovascular dysfunction, thermoregulatory issues, dysphagia and drooling, urinary symptoms, pain, neuropsychiatric symptoms, and sleep disorders, including obstructive sleep apnea, can be effectively treated with various dopaminergic strategies, while noting the contraindications and adverse effects of these therapies.<\/jats:p>","DOI":"10.3390\/ijms262411996","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:19:02Z","timestamp":1765556342000},"page":"11996","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Effect of Dopaminergic Therapies in Parkinson\u2019s Disease on Non-Motor Symptoms"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1410-0681","authenticated-orcid":false,"given":"Monika","family":"Jampolska","sequence":"first","affiliation":[{"name":"Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-4736","authenticated-orcid":false,"given":"Katarzyna","family":"Kaczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"ref_1","first-page":"13","article-title":"Brain monoamines and parkinsonism","volume":"3","author":"Hornykiewicz","year":"1975","journal-title":"Aminergic Hypotheses of Behavior, Reality or Cliche?"},{"key":"ref_2","first-page":"9","article-title":"The discovery of dopamine deficiency in the parkinsonian brain","volume":"70","author":"Hornykiewicz","year":"2006","journal-title":"J. Neural. Transm. Suppl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0072-9752(07)83026-0","article-title":"Neuroinflammation and Parkinson\u2019s disease","volume":"83","author":"Przedborski","year":"2007","journal-title":"Handb. Clin. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.55782\/ane-1998-1262","article-title":"Motor deficiency in Parkinson\u2019s disease","volume":"58","year":"1998","journal-title":"Acta Neurobiol. Exp."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","article-title":"Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson\u2019s disease","volume":"275","author":"Scatton","year":"1983","journal-title":"Brain Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson\u2019s disease: Dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.nicl.2017.03.011","article-title":"Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson\u2019s disease","volume":"14","author":"Caminiti","year":"2017","journal-title":"Neuroimage Clin."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Acharya, S., and Kim, K.M. (2021). Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094299"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","article-title":"Recent Advances in Drug Therapy for Parkinson\u2019s Disease","volume":"62","author":"Murakami","year":"2023","journal-title":"Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.12688\/f1000research.10100.1","article-title":"Recent advances in treating Parkinson\u2019s disease","volume":"6","author":"Oertel","year":"2017","journal-title":"F1000Research"},{"key":"ref_12","unstructured":"Zahoor, I., Shafi, A., and Haq, E. (2018). Pharmacological Treatment of Parkinson\u2019s Disease. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamaneurol.2021.4736","article-title":"Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial","volume":"79","author":"Gray","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","article-title":"A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease","volume":"129","author":"Jost","year":"2022","journal-title":"J. Neural. Transm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/B978-0-12-381326-8.00009-0","article-title":"Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson\u2019s disease","volume":"95","author":"Kaakkola","year":"2010","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.12.023","article-title":"Long-term study of ropinirole patch in Parkinson\u2019s disease patients with\/without basal L-dopa","volume":"83","author":"Mochizuki","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00228-020-02961-6","article-title":"Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson\u2019s disease: A multiple treatment comparison meta-analysis","volume":"76","author":"Binde","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_18","first-page":"37","article-title":"Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: A mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J. Biol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lin, I.C., Wang, Y.H., Wang, T.J., Wang, I.J., Shen, Y.D., Chi, N.F., and Chien, L.N. (2014). Glaucoma, Alzheimer\u2019s disease, and Parkinson\u2019s disease: An 8-year population-based follow-up study. PLoS ONE, 9, Correction in PLoS ONE 2016, 11, e0150789.","DOI":"10.1371\/journal.pone.0150789"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.14802\/jmd.23037","article-title":"Investigation of the Long-Term Effects of Amantadine Use in Parkinson\u2019s Disease","volume":"16","author":"Park","year":"2023","journal-title":"J. Mov. Disord."},{"key":"ref_22","unstructured":"Chang, C., and Ramphul, K. (2025, November 12). Amantadine, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499953\/."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cuenca-Bermejo, L., Almela, P., Navarro-Zaragoza, J., Villalba, E.F., Gonz\u00e1lez-Cuello, A.M., Laorden, M.L., and Herrero, M.-T. (2021). Cardiac Changes in Parkinson\u2019s Disease: Lessons from Clinical and Experimental Evidence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413488"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3892\/br.2023.1607","article-title":"Parkinson\u2019s disease and cardiovascular involvement: Edifying insights (Review)","volume":"18","author":"Grosu","year":"2023","journal-title":"Biomed. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(03)00555-6","article-title":"Dysautonomia in Parkinson\u2019s disease: Neurocardiological abnormalities","volume":"2","author":"Goldstein","year":"2003","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s13311-020-00897-4","article-title":"Autonomic Dysfunction in Parkinson\u2019s Disease","volume":"17","author":"Pfeiffer","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.parkreldis.2014.04.007","article-title":"Cardiovascular effects of levodopa in Parkinson\u2019s disease","volume":"20","author":"Noack","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_28","first-page":"75","article-title":"Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment","volume":"13","author":"Vural","year":"2016","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105860","DOI":"10.1016\/j.parkreldis.2023.105860","article-title":"Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson\u2019s disease: Results of acute levodopa challenge test","volume":"115","author":"Liu","year":"2023","journal-title":"Park. Relat. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e17876","DOI":"10.1016\/j.heliyon.2023.e17876","article-title":"Effects of different levodopa doses on blood pressure in older patients with early and middle stages of Parkinson\u2019s disease","volume":"9","author":"Su","year":"2023","journal-title":"Heliyon"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e16061","DOI":"10.1111\/ene.16061","article-title":"Levodopa-induced orthostatic hypotension in parkinsonism: A red flag of autonomic failure","volume":"31","author":"Cani","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","article-title":"Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry","volume":"21","author":"Buongiorno","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2017.02.001","article-title":"Levodopa\/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson\u2019s disease: An open-label study","volume":"37","author":"Aschermann","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mdc3.12526","article-title":"Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson\u2019s Disease","volume":"4","author":"Standaert","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_35","unstructured":"Choi, J., and Horner, K.A. (2025, November 13). Dopamine Agonists, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551686\/."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1017\/cjn.2017.284","article-title":"Improvement in Severe Orthostatic Hypotension Following Carbidopa Dose Reduction","volume":"45","author":"Lau","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","article-title":"Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: Practical considerations","volume":"130","author":"Regensburger","year":"2023","journal-title":"J. Neural. Transm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/14740338.2014.888057","article-title":"Risk of heart failure following treatment with dopamine agonists in Parkinson\u2019s disease patients","volume":"13","author":"Rey","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(84)90364-0","article-title":"Dopamine effects on thermosensitive neurons in hypothalamic tissue slices","volume":"306","author":"Scott","year":"1984","journal-title":"Brain Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/B978-0-444-64074-1.00043-4","article-title":"Thermoregulation in Parkinson disease","volume":"157","author":"Coon","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1755-5949.2012.00375.x","article-title":"Severe hypothermia in Parkinson\u2019s disease","volume":"18","author":"Li","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1212\/CPJ.0000000000000402","article-title":"Spontaneous periodic hypothermia in Parkinson disease with hypothalamic involvement","volume":"7","author":"Renga","year":"2017","journal-title":"Neurol. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1212\/WNL.0000000000212610","article-title":"Hypothermia in Parkinson\u2019s Disease and Related Disorders: A Case Series (P9-5.032)","volume":"104","author":"Blake","year":"2025","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"omy089","DOI":"10.1093\/omcr\/omy089","article-title":"Accidental hypothermia in Parkinson\u2019s disease","volume":"2018","author":"Kataoka","year":"2018","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1353-8020(02)00035-4","article-title":"Neuroleptic malignant syndrome-like, or\u2014Dopaminergic malignant syndrome\u2014Due to levodopa therapy withdrawal. Clinical features in 11 patients","volume":"9","year":"2003","journal-title":"Park. Relat. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.parkreldis.2016.12.018","article-title":"Dyskinesia-hyperpyrexia syndrome under continuous dopaminergic stimulation","volume":"36","year":"2017","journal-title":"Park. Relat Disord"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/mdc3.12663","article-title":"Dyskinesia-Hyperpyrexia Syndrome in Parkinson\u2019s Disease: A Heat Shock-Related Emergency?","volume":"5","author":"Sarchioto","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s00415-019-09325-w","article-title":"Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson\u2019s disease","volume":"266","author":"Leta","year":"2019","journal-title":"J. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1353-8020(02)00122-0","article-title":"A collaborative study on the malignant syndrome in Parkinson\u2019s disease and related disorders","volume":"9","author":"Takubo","year":"2003","journal-title":"Park. Relat. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/mds.21422","article-title":"Sweating in Parkinsonian patients with wearing-off","volume":"22","author":"Pursiainen","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105489","DOI":"10.1016\/j.parkreldis.2023.105489","article-title":"Sudomotor deficits in Parkinson\u2019s disease with special reference to motor subtypes","volume":"114","author":"Saito","year":"2023","journal-title":"Park. Relat. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2016.12.070","article-title":"Dopamine agonist withdrawal syndrome: A comprehensive review","volume":"374","author":"Yu","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"vii42","DOI":"10.1007\/s00415-006-7010-7","article-title":"Sweating dysfunctions in Parkinson\u2019s disease","volume":"253","author":"Hirayama","year":"2006","journal-title":"J. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.410370124","article-title":"Drenching sweats as an off phenomenon in Parkinson\u2019s disease: Treatment and relation to plasma levodopa profile","volume":"37","author":"Sage","year":"1995","journal-title":"Ann. Neurol."},{"key":"ref_55","first-page":"197","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: A real life study of non motor effect","volume":"1","author":"Reddy","year":"2011","journal-title":"J. Park. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s40141-023-00392-9","article-title":"Dysphagia in Parkinson Disease: Part I\u2014Pathophysiology and Diagnostic Practices","volume":"11","author":"Rudisch","year":"2023","journal-title":"Curr. Phys. Med. Rehabil. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Isaacson, J., Patel, S., Torres-Yaghi, Y., and Pag\u00e1n, F. (2020). Sialorrhea in Parkinson\u2019s Disease. Toxins, 12.","DOI":"10.3390\/toxins12110691"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.parkreldis.2012.11.007","article-title":"Dysphagia in Parkinson\u2019s disease is responsive to levodopa","volume":"19","author":"Sutton","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2016.04.034","article-title":"Levodopa responsiveness of dysphagia in advanced Parkinson\u2019s disease and reliability testing of the FEES-Levodopa-test","volume":"28","author":"Warnecke","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/bs.irmvd.2021.07.003","article-title":"Drooling and dysphagia in Parkinson\u2019s disease","volume":"1","author":"Merello","year":"2021","journal-title":"International Review of Movement Disorders"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00455-015-9622-5","article-title":"Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson\u2019s Disease","volume":"30","author":"Hirano","year":"2015","journal-title":"Dysphagia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000488138","article-title":"Dysphagia Causes Symptom Fluctuations after Oral L-DOPA Treatment in a Patient with Parkinson Disease","volume":"10","author":"Sato","year":"2018","journal-title":"Case Rep. Neurol."},{"key":"ref_63","first-page":"37","article-title":"Does amantadine help elderly residents with symptomless dysphagia?","volume":"19","author":"Gokula","year":"2011","journal-title":"Ann. Long-Term Care"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11255-011-9969-y","article-title":"Urinary tract dysfunction in Parkinson\u2019s disease: A review","volume":"44","author":"Yeo","year":"2012","journal-title":"Int. Urol. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/iju.12421","article-title":"Bladder function of patients with Parkinson\u2019s disease","volume":"21","author":"Sakakibara","year":"2014","journal-title":"Int. J. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/nau.22455","article-title":"Central nervous targets for the treatment of bladder dysfunction","volume":"33","author":"Yoshimura","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"116625","DOI":"10.1016\/j.jns.2019.116625","article-title":"Extended release levodopa at bedtime as a treatment for nocturiain Parkinson\u2019s disease: An open label study","volume":"410","author":"Brusa","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1212\/01.wnl.0000260605.12506.86","article-title":"Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease","volume":"68","author":"Brusa","year":"2007","journal-title":"Neurology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.parkreldis.2014.04.020","article-title":"Rasagiline effect on bladder disturbances in early mild Parkinson\u2019s disease patients","volume":"20","author":"Brusa","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","article-title":"Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson\u2019s disease","volume":"40","author":"Bianchi","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-L\u00f3pez, A., S\u00e1nchez-S\u00e1nchez, A., Natera-Villalba, E., Ros-Castell\u00f3, V., Beltr\u00e1n-Corbellini, \u00c1., Fanjul-Arb\u00f3s, S., Pare\u00e9s Moreno, I., L\u00f3pez-Sendon Moreno, J.L., Mart\u00ednez Castrillo, J.C., and Alonso-Canovas, A. (2021). SURINPARK: Safinamide for Urinary Symptoms in Parkinson\u2019s Disease. Brain Sci., 11.","DOI":"10.3390\/brainsci11010057"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10072-021-05324-w","article-title":"Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson\u2019s disease patients: A prospective longitudinal study","volume":"43","author":"Satolli","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_73","first-page":"21","article-title":"Amantadine can Ameliorate Lower Urinary Tract Dysfunction and Nocturnal Polyuria in Patients with Parkinson Disease and Vascular Parkinsonism","volume":"42","author":"Hiromi","year":"2015","journal-title":"Dokkyo J. Med. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/mdc3.12488","article-title":"Rotigotine Effects on Bladder Function in Patients with Parkinson\u2019s Disease","volume":"4","author":"Brusa","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_75","first-page":"381","article-title":"Sleep and Parkinson Disease","volume":"114","author":"Bollu","year":"2017","journal-title":"Mo. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41531-024-00642-0","article-title":"Sleep disorders in Parkinson\u2019s disease, an early and multiple problem","volume":"10","author":"Dodet","year":"2024","journal-title":"NPJ Park. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(24)00170-4","article-title":"Sleep and sleep disorders in people with Parkinson\u2019s disease","volume":"23","author":"Iranzo","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/bs.irn.2017.05.033","article-title":"Sleep Dysfunction in Parkinson\u2019s Disease","volume":"133","author":"Diaconu","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1002\/mds.22788","article-title":"Sleep disturbances in Parkinson\u2019s disease","volume":"25","author":"Menza","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.2174\/1570159X19666210517115706","article-title":"Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson\u2019s Disease","volume":"19","author":"Taximaimaiti","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.5664\/jcsm.10450","article-title":"An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson\u2019s disease","volume":"19","author":"Scanga","year":"2023","journal-title":"J. Clin. Sleep Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1080\/14656566.2024.2422004","article-title":"Pharmacological and non-pharmacological management of sleep disturbances in Parkinson\u2019s disease: If when and how","volume":"25","author":"Muntean","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/0118715273314675240820191447","article-title":"Sleep-Related Disorders in Parkinson\u2019s Disease: Mechanisms, Diagnosis, and Therapeutic Approaches","volume":"24","author":"Hamid","year":"2025","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jsmc.2025.06.004","article-title":"Pharmacological Management of Insomnia in Parkinson\u2019s Disease","volume":"20","author":"Domaszewicz","year":"2025","journal-title":"Sleep Med. Clin."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Diaconu, \u015e., Irincu, L., \u0162\u00een\u0163, D., and Falup-Pecurariu, C. (2023). Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson\u2019s disease. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1105650"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"205","DOI":"10.14802\/jmd.20055","article-title":"Therapeutic Effect of Levodopa\/Carbidopa\/Entacapone on Sleep Disturbance in Patients with Parkinson\u2019s Disease","volume":"13","author":"Park","year":"2020","journal-title":"J. Mov. Disord."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00415-021-10419-7","article-title":"Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson\u2019s Disease","volume":"268","author":"Schaeffer","year":"2021","journal-title":"J. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"106971","DOI":"10.1016\/j.parkreldis.2024.106971","article-title":"OFF-times before, during, and after nighttime sleep periods in Parkinson\u2019s disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2","volume":"123","author":"Hauser","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"ref_89","first-page":"87","article-title":"Opicapone for Parkinson\u2019s disease-related sleep disturbances: The OASIS clinical trial","volume":"15","author":"Ferreira","year":"2025","journal-title":"J. Park. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1007\/s00415-024-12351-y","article-title":"Effects of dopaminergic therapy on sleep quality in fluctuating Parkinson\u2019s disease patients","volume":"271","author":"Ledda","year":"2024","journal-title":"J. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Grigoriou, S., Janz, C., Horne, M., Bergquist, F., Dizdar, N., and Odin, P. (2025). Effects of rotigotine on sleep in Parkinson\u2019s disease patients: A Parkinson\u2019s KinetiGraph study. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1591537"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sportelli, C., Poplawska-Domaszewicz, K., Borley, C., Metta, V., Leta, V., Wu, K., Sauerbier, A., Santoro, C., Landolfo, S., and Urso, D. (2025). \u201cDozing off\u201d in the car and excessive daytime sleepiness (EDS) in Parkinson\u2019s disease: A survey of 125 patients. J. Neural. Transm.","DOI":"10.1007\/s00702-025-02995-z"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease","volume":"30","author":"Reddy","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","article-title":"Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): A multicentre, randomised, controlled, double-blind crossover study","volume":"21","author":"Dodet","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41531-022-00339-2","article-title":"Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson\u2019s disease: A systematic review","volume":"8","author":"Tsuboi","year":"2022","journal-title":"NPJ Park. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Solleiro Vidal, \u00c1., Y\u00e1\u00f1ez Ba\u00f1a, R., Labandeira Guerra, C., Cimas Hernando, M.I., Cabo L\u00f3pez, I., Paz Gonz\u00e1lez, J.M., Alonso Losada, M.G., and Santos Garc\u00eda, D. (2025). Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson\u2019s Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose. Brain Sci., 15.","DOI":"10.20944\/preprints202505.2287.v1"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s10072-021-05607-2","article-title":"Safinamide improves sleep and daytime sleepiness in Parkinson\u2019s disease: Results from the SAFINONMOTOR study","volume":"43","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00702-023-02603-y","article-title":"The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson\u2019s disease: Opicapone versus entacapone","volume":"130","author":"Leta","year":"2023","journal-title":"J. Neural. Transm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40120-021-00246-3","article-title":"Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson\u2019s Disease and Dyskinesia","volume":"10","author":"Mehta","year":"2021","journal-title":"Neurol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2147\/NSS.S478860","article-title":"Sleep Disturbance in Parkinson\u2019s Disease: Consequences for the Brain and Disease Progression\u2014A Narrative Review","volume":"17","author":"Anderson","year":"2025","journal-title":"Nat. Sci. Sleep"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e16109","DOI":"10.1111\/ene.16109","article-title":"Prevalence and clinical aspects of obstructive sleep apnea in Parkinson disease: A meta-analysis","volume":"31","author":"Maggi","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101281","DOI":"10.1016\/j.smrv.2020.101281","article-title":"Sleep in Parkinson\u2019s disease: A systematic review and meta-analysis of polysomnographic findings","volume":"51","author":"Zhang","year":"2020","journal-title":"Sleep Med. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.5664\/jcsm.10596","article-title":"Bidirectional association between Parkinson\u2019s disease and obstructive sleep apnea: A cohort study","volume":"19","author":"Jeon","year":"2023","journal-title":"J. Clin. Sleep Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2147\/NDT.S134311","article-title":"Sleep apnea and the subsequent risk of Parkinson\u2019s disease: A 3-year nationwide population-based study","volume":"13","author":"Chou","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Valko, P.O., Hauser, S., Sommerauer, M., Werth, E., and Baumann, C.R. (2014). Observations on sleep-disordered breathing in idiopathic Parkinson\u2019s disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100828"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11325-015-1208-9","article-title":"Obstructive sleep apnea in Parkinson\u2019s disease patients: Effect of Sinemet CR taken at bedtime","volume":"20","author":"Gros","year":"2016","journal-title":"Sleep Breath."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1378\/chest.96.1.210","article-title":"Reversibility of upper airway obstruction after levodopa therapy in Parkinson\u2019s disease","volume":"96","author":"Vincken","year":"1989","journal-title":"Chest"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1378\/chest.119.2.387","article-title":"Effects of levodopa on pulmonary function in Parkinson\u2019s disease","volume":"119","author":"Herer","year":"2001","journal-title":"Chest"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.sleep.2014.09.014","article-title":"Supine sleep and obstructive sleep apnea syndrome in Parkinson\u2019s disease","volume":"16","author":"Driss","year":"2015","journal-title":"Sleep Med."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Kaczy\u0144ska, K., Or\u0142owska, M.E., and Andrzejewski, K. (2022). Respiratory Abnormalities in Parkinson\u2019s Disease: What Do We Know from Studies in Humans and Animal Models?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073499"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.sleep.2024.07.015","article-title":"Prevalence and clinical profile of patients with restless legs syndrome in Parkinson\u2019s disease: A meta-analysis","volume":"121","author":"Maggi","year":"2024","journal-title":"Sleep Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00415-025-13288-6","article-title":"Restless legs syndrome in Parkinson\u2019s disease: Epidemiology, pathogenetic overlaps, and clinical management","volume":"272","author":"Wang","year":"2025","journal-title":"J. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11325-016-1414-0","article-title":"An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson\u2019s disease","volume":"21","author":"Wang","year":"2017","journal-title":"Sleep Breath."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1021\/acschemneuro.0c00332","article-title":"Classics in Chemical Neuroscience: Pramipexole","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11940-019-0596-8","article-title":"Therapies for Restless Legs in Parkinson\u2019s Disease","volume":"21","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.sleep.2017.11.1139","article-title":"Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome","volume":"44","author":"Kim","year":"2018","journal-title":"Sleep Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1185\/03007995.2014.946124","article-title":"A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome","volume":"30","author":"Sun","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0043-1770810","article-title":"A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome","volume":"16","author":"Madhaw","year":"2023","journal-title":"Sleep Sci."},{"key":"ref_119","first-page":"j104","article-title":"New concepts in the management of restless legs syndrome","volume":"356","year":"2017","journal-title":"BMJ"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mdc3.12217","article-title":"Pain in Parkinson\u2019s Disease: Current Concepts and a New Diagnostic Algorithm","volume":"2","author":"Mylius","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_121","first-page":"1","article-title":"An overview of pain in Parkinson\u2019s disease","volume":"2","author":"Tai","year":"2020","journal-title":"Clin. Park. Relat. Disord."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"132","DOI":"10.31083\/j.jin2205132","article-title":"Pain in Parkinson\u2019s Disease: Pathophysiology, Classification and Treatment","volume":"22","author":"Cattaneo","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/ejp.1413","article-title":"Unveiling the relationship between central parkinsonian pain and motor symptoms in Parkinson\u2019s disease","volume":"23","author":"Cavaco","year":"2019","journal-title":"Eur. J. Pain"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e4765","DOI":"10.1002\/ejp.4765","article-title":"Pain in Parkinson\u2019s disease is impacted by motor complications, anxiety and sleep disturbances","volume":"29","author":"Rukavina","year":"2025","journal-title":"Eur. J. Pain"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/14737175.2017.1385393","article-title":"Pharmacological therapies for pain in Parkinson\u2019s disease\u2014A review paper","volume":"17","author":"Rana","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jns.2018.10.013","article-title":"Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation","volume":"395","author":"Sung","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Li, J., Zhu, B.F., Gu, Z.Q., Zhang, H., Mei, S.S., Ji, S.Z., Liu, S.Y., Han, C., Chen, H.Z., and Chan, P. (2022). Musculoskeletal Pain in Parkinson\u2019s Disease. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.756538"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e1874205X2209260","DOI":"10.2174\/1874205X-v16-e220927-2022-6","article-title":"Chronic Pain and Levodopa Therapy in Parkinson\u2019s Disease Patients","volume":"16","author":"Camargo","year":"2022","journal-title":"Open Neurol. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jcph.678","article-title":"A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson\u2019s Disease-Associated Chronic Pain","volume":"56","author":"Rascol","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"123051","DOI":"10.1016\/j.jns.2024.123051","article-title":"Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson\u2019s disease with wearing-off: The Japanese observational J-SILVER study","volume":"461","author":"Nishikawa","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","article-title":"Long-term Efficacy of Safinamide on Parkinson\u2019s Disease Chronic Pain","volume":"35","author":"Cattaneo","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Garc\u00eda, D.S., Guerra, C.L., Ba\u00f1a, R.Y., Hernando, M.I.C., L\u00f3pez, I.C., Paz Gon\u00e1lez, J.M., Alonso Losada, M.G., Gonz\u00e1lez Palm\u00e1s, M.J., and Mart\u00ednez Mir\u00f3, C. (2021). Safinamide Improves Non-Motor Symptoms Burden in Parkinson\u2019s Disease: An Open-Label Prospective Study. Brain Sci., 11.","DOI":"10.3390\/brainsci11030316"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-018-0119-7","article-title":"Adjunct rasagiline to treat Parkinson\u2019s disease with motor fluctuations: A randomized, double-blind study in China","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl. Neurodegener."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.04.025","article-title":"Efficacy and safety of adjunctive rasagiline in Japanese Parkinson\u2019s disease patients with wearing-off phenomena: A phase 2\/3, randomized, double-blind, placebo-controlled, multicenter study","volume":"53","author":"Hattori","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Solla, P., Ercoli, T., Masala, C., Orofino, G., Fadda, L., Corda, D.G., Zarbo, I.R., Meloni, M., Sechi, E., and Bagella, C.F. (2022). Rasagiline Withdrawal Syndrome in Parkinson\u2019s Disease. Brain Sci., 12.","DOI":"10.3390\/brainsci12020219"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson\u2019s Disease","volume":"59","author":"Kaakkola","year":"2000","journal-title":"Drugs"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1213\/01.ane.0000196691.82989.67","article-title":"Amantadine sulfate reduces experimental sensitization and pain in chronic back pain patients","volume":"102","author":"Bender","year":"2006","journal-title":"Anesth. Analg."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"106088","DOI":"10.1016\/j.parkreldis.2024.106088","article-title":"Extended-release amantadine for OFF-related dystonia in Parkinson\u2019s disease","volume":"122","author":"Espay","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3344\/kjp.24245","article-title":"Characterizing pain in Parkinson\u2019s disease: Types, predictors, and management implications","volume":"38","author":"Alis","year":"2025","journal-title":"Korean J. Pain"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Dlay, J.K., Duncan, G.W., Khoo, T.K., Williams-Gray, C.H., Breen, D.P., Barker, R.A., Burn, D.J., Lawson, R.A., and Yarnall, A.J. (2020). Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson\u2019s Disease Cohort (ICICLE-PD). Brain Sci., 10.","DOI":"10.3390\/brainsci10020078"},{"key":"ref_142","first-page":"1213393","article-title":"Neuropsychiatric Symptoms in Clinically Defined Parkinson\u2019s Disease: An Updated Review of Literature","volume":"2022","author":"Sanmartino","year":"2022","journal-title":"Behav. Neurol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jagp.2016.08.017","article-title":"Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care","volume":"24","author":"Taylor","year":"2016","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Angelopoulou, E., Stanitsa, E., Karpodini, C.C., Bougea, A., Kontaxopoulou, D., Fragkiadaki, S., Koros, C., Georgakopoulou, V.G., Fotakopoulos, G., and Koutedakis, Y. (2023). Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson\u2019s Disease: An Updated Review. Medicina, 59.","DOI":"10.3390\/medicina59081454"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"17562864251356062","DOI":"10.1177\/17562864251356062","article-title":"Neuropsychiatric disorders in Parkinson\u2019s disease","volume":"18","author":"Heim","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/brain\/awy341","article-title":"Dopamine restores cognitive motivation in Parkinson\u2019s disease","volume":"142","author":"McGuigan","year":"2019","journal-title":"Brain"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"P04.195","DOI":"10.1212\/WNL.80.7_supplement.P04.195","article-title":"Levodopa Improves Psychiatric Symptoms of Parkinson\u2019s Disease More Than Dopamine Agonists (P04.195)","volume":"80","author":"Mcallister","year":"2013","journal-title":"Neurology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00415-018-8951-3","article-title":"Assessment of Duodopa\u00ae effects on quality of life of patients with advanced Parkinson\u2019s disease and their caregivers","volume":"265","author":"Ciurleo","year":"2018","journal-title":"J. Neurol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2018.08.003","article-title":"Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson\u2019s disease: A meta-analysis of randomized placebo-controlled trials","volume":"393","author":"He","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Yan, J., Ma, H., Liu, A., Huang, J., Wu, J., and Yang, J. (2021). Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson\u2019s Disease: An Updated Meta-Analysis and Systematic Review. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.722892"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40266-015-0264-y","article-title":"Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson\u2019s Disease: A Prospective, Cross-Sectional Study in Non-demented Patients","volume":"32","author":"Pagonabarraga","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and Management of Neuropsychiatric Symptoms in Parkinson\u2019s Disease","volume":"32","author":"Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_154","first-page":"1757","article-title":"Efficacy and safety of pramipexole in Parkinson\u2019s disease with anxiety or depression: A meta-analysis of randomized clinical trials","volume":"14","author":"Ji","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","article-title":"Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil","volume":"136","author":"Thobois","year":"2013","journal-title":"Brain"},{"key":"ref_156","first-page":"629","article-title":"Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson\u2019s Disease","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Park. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2045125320985993","DOI":"10.1177\/2045125320985993","article-title":"The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson\u2019s disease: Meta-analysis of randomized controlled trials","volume":"11","author":"Huang","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Santos Garc\u00eda, D., Fern\u00e1ndez Pajar\u00edn, G., Oropesa-Ruiz, J.M., Escamilla Sevilla, F., Rahim L\u00f3pez, R.R.A., and Mu\u00f1oz Enr\u00edquez, J.G. (2022). Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson\u2019s Disease: An Open-Label Prospective Study. Brain Sci., 12.","DOI":"10.3390\/brainsci12030383"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/nmt-2021-0057","article-title":"Opicapone in UK clinical practice: Effectiveness, safety and cost analysis in patients with Parkinson\u2019s disease","volume":"12","author":"Schofield","year":"2022","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/NDT.S54423","article-title":"Amantadine and cognitive flexibility: Decision making in Parkinson\u2019s patients with severe pathological gambling and other impulse control disorders","volume":"10","author":"Cera","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11055-011-9456-z","article-title":"Effects of Amantadine Sulfate on Cognitive Impairments in Patients with Parkinson\u2019s Disease","volume":"41","author":"Yablonskaya","year":"2011","journal-title":"Neurosci. Behav. Physiol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Bougea, A., Efthymiopoulou, \u0395., Degirmenci, Y., and Zikos, P. (2025). Amantadine improves executive and memory functions in patients with Parkinsons Disease: Double blind parallel two-arm randomized controlled trial. preprint.","DOI":"10.21203\/rs.3.rs-7142916\/v1"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/11996\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:25:02Z","timestamp":1765949102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/11996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":162,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262411996"],"URL":"https:\/\/doi.org\/10.3390\/ijms262411996","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}